PALO ALTO, Calif., Nov. 18, 2020 /PRNewswire/ -- Inpixon
(Nasdaq: INPX), the Indoor Intelligence™ company, today announced
that Inpixon Mapping has been selected by one of the world's
premier pharmaceutical companies to provide the visualization
required for tracking its critical COVID-19 vaccine-related assets.
Inpixon Mapping is currently contracted for deployment in multiple
facilities utilized by this company, which specializes in the
development of medicines and vaccines across a wide range of
disciplines, and multiple additional locations are anticipated to
be added over the coming weeks and months.
Inpixon Mapping will be used to view the location of tagged
assets on a dynamic, multi-layered map in near real-time within
this pharmaceutical company's facilities. The terms of the customer
agreement include both one-time professional services revenue, as
well as recurring revenue associated with the mapping platform
license.
Nadir Ali, CEO of Inpixon,
commented, "We are proud that our mapping platform was selected by
this leading pharmaceutical company to provide the visualization
required for tracking vital assets as part of the effort to combat
the COVID-19 pandemic. This most recent contract serves as a
prime illustration of how our technology can assist in addressing
critical supply chain requirements.
"Our Indoor Intelligence solutions continue to attract the
attention of leading organizations, and we are rolling out our
solutions in some of the most recognized companies in the world. We
appreciate the trust and confidence each of these companies has
placed in our technology and our team. Of particular note, the
opportunity to provide our mapping solution for this pharmaceutical
company's COVID-19 vaccine-related work, which is so critically
important to all our lives and to help eradicate the pandemic, is a
great honor for our company."
Inpixon's Indoor Intelligence platform is a comprehensive
solution for indoor positioning, mapping, security and analytics.
Additionally, the platform's Workplace Readiness™ dashboards
facilitate contact tracing, social distancing and targeted cleaning
to help enterprises create safer workplaces.
About Inpixon
Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that
specializes in capturing, interpreting and giving context to indoor
data so it can be translated into actionable intelligence. The
company's Indoor Intelligence platform ingests diverse data from
IoT, third-party and proprietary sensors designed to detect and
position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired
with a high-performance data analytics engine, patented algorithms,
and advanced mapping technology, Inpixon's solutions are leveraged
by a multitude of industries to do good with indoor data. This
multidisciplinary depiction of indoor data enables users to
increase revenue, decrease costs, and enhance safety. Inpixon
customers can boldly take advantage of location awareness,
analytics, sensor fusion and the Internet of Things (IoT) to
uncover the untold stories of the indoors. For the latest insights,
follow Inpixon on LinkedIn, Twitter, and
visit inpixon.com.
Safe Harbor Statement
All statements in this release that are not based on
historical fact are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and the
provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. While management has based any forward-looking statements
included in this release on its current expectations, the
information on which such expectations were based may change. These
forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties and other factors, many of which are outside of the
control of Inpixon and its subsidiaries, which could cause
actual results to materially differ from such statements.
Such risks, uncertainties, and other factors include, but are not
limited to, the fluctuation of economic conditions, the impact of
COVID-19 on Inpixon's results of operations, Inpixon's
ability to integrate the products and business from recent
acquisitions into its existing business, the performance of
management and employees, the regulatory landscape as it relates to
privacy regulations and their applicability to Inpixon's
technology, Inpixon's ability to maintain compliance with Nasdaq's
minimum bid price requirement and other continued
listing requirements, including during a panel monitoring period
ending on February 5, 2021, the
ability to obtain financing, competition, general economic
conditions and other factors that are detailed in Inpixon's
periodic and current reports available for review at sec.gov.
Furthermore, Inpixon operates in a highly competitive and rapidly
changing environment where new and unanticipated risks may arise.
Accordingly, investors should not place any reliance on
forward-looking statements as a prediction of actual results.
Inpixon disclaims any intention to, and undertakes no obligation
to, update or revise forward-looking statements.
Inpixon Contacts
Media relations and general inquiries:
Inpixon
Email: marketing@inpixon.com
Web: inpixon.com/contact-us
Investor relations:
Crescendo Communications, LLC
Tel: +1 212-671-1020
Email: INPX@crescendo-ir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/inpixon-mapping-selected-by-leading-pharmaceutical-corporation-to-facilitate-tracking-of-covid-19-vaccine-related-assets-301175611.html
SOURCE Inpixon